1. Scrip
  2. >>Business
  3. >>Deals

Pfizer Shopping For Deals That Will Add $25bn To 2030 Revenues

 
• By Jessica Merrill

With cash to spend and a patent cliff to overcome starting in 2025, Pfizer is expected to be a prolific deal-maker in 2022.

shopping cart
Pfizer has money to spend on deals • Source: Alamy

Pfizer Inc. has the cash to spend on business development, and CEO Albert Bourla told investors the company is aiming to sign deals that will add $25bn of risk-adjusted revenue to the top line by 2030. During the firm’s fourth quarter sales and earnings call on 8 February, Pfizer's management outlined the current thinking on allocating the windfall of cash it has stockpiled.

The success of Pfizer's COVID-19 vaccine Comirnaty and oral antiviral Paxlovid (nirmatrelvir/ritonavir) have strengthened the company's financial flexibility to do deals, and stakeholders across the industry are wondering what Pfizer will buy or in-license next. As the company revealed during its fourth quarter earnings, 2022 is going to be a windfall of a year for Pfizer; the big pharma expects to generate more than $100bn in revenue for the first time in 2022, including $32bn from Comirnaty and $22bn from Paxlovid, estimates that are considered conservative

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.